Effects and mechanism of the selective COX‐2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid
Authors:
- 9 July 2004
- journal article
- Published by Wiley in Chinese Journal of Digestive Diseases
- Vol. 5 (3) , 110-114
Abstract
OBJECTIVE: To investigate the action of celecoxib (a selective COX‐2 inhibitor) in a rat model of colitis induced by trinitrobenzene sulfonic acid (TNBS).METHODS: Rats were randomized into four groups. Colitis was induced in groups 1 and 2 by intracolonic administration of TNBS (25 mg/mL) in 50% ethanol (0.25 mL). The rats in group 1 received oral celecoxib (1.25 mg/kg) and those in group 2 received distilled water (1 mL/0.3 kg), beginning 3 h before induction of colitis and continuing twice daily thereafter for up to 7 days. The rats in group 4 received oral celecoxib (1.25 mg/kg) twice daily for 7 days and those in group 3 were healthy controls. All rats that survived 7 days were killed and both the severity of colonic mucosal damage and the prostaglandin E2 (PGE2) concentrations of the colonic mucosa were assessed.RESULTS: The colonic mucosal damage scores for groups 1 and 2 were 11.15 ± 3.30 and 8.50 ± 2.82, respectively, both of which were significantly higher than the score for the healthy controls (0.62 ± 0.09; P < 0.01, P < 0.01). The score of group 1 was significantly higher than that of group 2 (P < 0.05). No difference was found between the scores of groups 3 and 4. The mucosal concentrations of PGE2 in groups 1 and 2 were 12.00 ± 4.33 pg/µg and 17.20 ± 9.62 pg/µg, respectively, both of which were significantly higher than the concentration in the healthy controls (6.02 ± 3.39 pg/µg; P < 0.05, both). The PGE2 concentration of group 1 was decreased significantly compared with that of group 2 (P < 0.05). No difference was found between groups 3 and 4.CONCLUSION: The results suggest that treatment with celecoxib exacerbates inflammation‐associated colonic injury in experimental colitis induced by TNBS. This preliminary study shows that the mechanism is related to suppression by the COX‐2 inhibitor of the PG derived from COX‐2, but further study is needed to identify if there are other related mechanisms.Keywords
This publication has 16 references indexed in Scilit:
- Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel diseaseAmerican Journal of Gastroenterology, 2002
- Specific inhibition of cyclooxygenase‐2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 productionJournal of Oral Pathology & Medicine, 2001
- The Role of Cyclooxygenase 2 in Ulcerative Colitis-Associated NeoplasiaThe American Journal of Pathology, 2000
- Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel diseaseGastroenterology, 1998
- Inflammatory bowel disease: Etiology and pathogenesisGastroenterology, 1998
- Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.Journal of Clinical Investigation, 1996
- Eicosanoids and the gastrointestinal tractGastroenterology, 1995
- Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitisGastroenterology, 1990
- Treatment With 16, 16'-Dimethyl Prostaglandin E2 Before and After Induction of Colitis With Trinitrobenzenesulfonic Acid in Rats Decreases InflammationGastroenterology, 1989
- Effects of 16,16-dimethyl prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit colitisProstaglandins, 1988